EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems

Annalisa Di Rienzo iD, Lisa Marinelli, Marilisa Pia Dimmito iD, Eleonora Chiara Toto, Antonio Di Stefano iD, Ivana Cacciatore iD

Pharmaceutics · 07.09.2024 · 16 (9) · 1185

DOI: 10.3390/pharmaceutics16091185 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 07.09.2024. Verfasst von Annalisa Di Rienzo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disorder with two main subtypes: ulcerative colitis (UC) and Crohn’s disease (CD). The pathogenesis involves genetic predisposition, dysbiosis, and immune dysregulation. Complications include perianal lesions, strictures, fistulas, perforations, and an increased risk of colon cancer. Clinical classification ranges from mild to fulminant and recurrent disease, with common symptoms such as abdominal discomfort, rectal bleeding, diarrhea, and weight loss. Extraintestinal manifestations include arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis. Conventional treatments using aminosalicylates, corticosteroids, and immunomodulators have limitations. Biologics, introduced in the 1990s, offer improved efficacy and specificity, targeting factors like TNF-α, integrins, and cytokines. Monoclonal antibodies play a crucial role in IBD management, aiming to reduce relapses, hospitalizations, and surgeries. In conclusion, this review is aimed at summarizing the latest knowledge, advantages, and drawbacks of IBD therapies, such as small molecules, biologics, and monoclonal antibodies, to provide a basis for further research in the IBD field.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseasegastrointestinal inflammationinflammatory bowel diseasemonoclonal antibodiesulcerative colitis

Autor:innen und Institutionen

  • Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.

ORCID-Profile: Annalisa Di Rienzo, Marilisa Pia Dimmito, Antonio Di Stefano, Ivana Cacciatore

Zitieren

APA

Di Rienzo, A., Marinelli, L., Dimmito, M. P., Toto, E. C., Di Stefano, A., & Cacciatore, I. (2024). Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems. Pharmaceutics, 16(9), 1185. https://doi.org/10.3390/pharmaceutics16091185

Vancouver

Di Rienzo A, Marinelli L, Dimmito MP, Toto EC, Di Stefano A, Cacciatore I. Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems. Pharmaceutics. 2024;16(9):1185. doi:10.3390/pharmaceutics16091185

BibTeX
@article{DiRienzo2024,
  author = {Di Rienzo, Annalisa and Marinelli, Lisa and Dimmito, Marilisa Pia and Toto, Eleonora Chiara and Di Stefano, Antonio and Cacciatore, Ivana},
  title = {Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1185},
  doi = {10.3390/pharmaceutics16091185}
}
Kostenlos starten →